Psychotic symptoms in the course of sunitinib treatment for advanced renal cell cancer. Two cases

The vascular endothelial growth factor (VEGF) receptor inhibitor sunitinib is a first-line treatment in most patients with metastatic renal cell carcinoma. No psychiatric adverse events have previously been reported. We describe two patients with psychotic symptoms, during treatment with sunitinib. Possible mechanisms of sunitinib-induced psychosis are discussed.